- Home
- NXP vs RLAY Comparison
NXP vs RLAY Comparison
Compare NXP & RLAY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NXP
- RLAY
- Stock Information
- Founded
- NXP 1992
- RLAY 2015
- Country
- NXP United States
- RLAY United States
- Employees
- NXP N/A
- RLAY N/A
- Industry
- NXP Trusts Except Educational Religious and Charitable
- RLAY Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- NXP Finance
- RLAY Health Care
- Exchange
- NXP Nasdaq
- RLAY Nasdaq
- Market Cap
- NXP 730.9M
- RLAY 723.1M
- IPO Year
- NXP N/A
- RLAY 2020
- Fundamental
- Price
- NXP $14.79
- RLAY $4.46
- Analyst Decision
- NXP
- RLAY Strong Buy
- Analyst Count
- NXP 0
- RLAY 10
- Target Price
- NXP N/A
- RLAY $20.11
- AVG Volume (30 Days)
- NXP 70.0K
- RLAY 2.9M
- Earning Date
- NXP 01-01-0001
- RLAY 02-20-2025
- Dividend Yield
- NXP 4.04%
- RLAY N/A
- EPS Growth
- NXP N/A
- RLAY N/A
- EPS
- NXP 0.54
- RLAY N/A
- Revenue
- NXP N/A
- RLAY $10,006,000.00
- Revenue This Year
- NXP N/A
- RLAY N/A
- Revenue Next Year
- NXP N/A
- RLAY N/A
- P/E Ratio
- NXP $26.81
- RLAY N/A
- Revenue Growth
- NXP N/A
- RLAY N/A
- 52 Week Low
- NXP $12.91
- RLAY $3.50
- 52 Week High
- NXP $14.89
- RLAY $11.16
- Technical
- Relative Strength Index (RSI)
- NXP 47.10
- RLAY 49.13
- Support Level
- NXP $14.75
- RLAY $3.50
- Resistance Level
- NXP $14.88
- RLAY $5.99
- Average True Range (ATR)
- NXP 0.18
- RLAY 0.54
- MACD
- NXP -0.02
- RLAY 0.02
- Stochastic Oscillator
- NXP 19.61
- RLAY 38.55
About NXP Nuveen Select Tax Free Income Portfolio
Nuveen Select Tax Free Income Portfolio is a diversified closed-end investment company. It seeks to provide current income and stable dividends, exempt from regular federal and designated state income taxes, consistent with the preservation of capital by investing primarily in a portfolio of municipal obligations.
About RLAY Relay Therapeutics Inc.
Relay Therapeutics Inc is a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies with the goal of bringing life-changing therapies to patients. the Dynamo platform integrates an array of leading-edge computational and experimental approaches designed to drug-protein targets that have previously been intractable or inadequately addressed. The company is advancing a pipeline of medicine candidates to address targets in precision oncology and genetic disease, including product candidates, RLY-4008, RLY-2608, and GDC-1971 (formerly known as RLY-1971).